A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder-Reference-Cited by-同舟云学术

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

Published:2019-05-08 Issue:491 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Bolognani Federico¹,del Valle Rubido Marta¹,Squassante Lisa²,Wandel Christoph²,Derks Michael³,Murtagh Lorraine¹,Sevigny Jeff¹^ORCID,Khwaja Omar¹,Umbricht Daniel¹,Fontoura Paulo²^ORCID

Affiliation:

1. Neuroscience, Ophthalmology, and Rare Diseases (NORD), Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Basel, Switzerland.

2. Product Development, F. Hoffmann–La Roche AG, Basel, Switzerland.

3. Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Roche Products Ltd., Welwyn, UK.

Abstract

In the VANILLA phase 2 clinical trial, balovaptan treatment resulted in improved adaptive behaviors in adult men with autism.

Funder

F. Hoffmann-La Roche Ltd.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference44 articles.

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (American Psychiatric Association Publishing 2013).

2. Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 National Health Interview Survey;Zablotsky B.;Natl. Health Stat. Rep.,2015

3. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014

4. Epidemiology of autism in adults across age groups and ability levels

5. Management of Children With Autism Spectrum Disorders

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity;Acta Pharmaceutica Sinica B;2024-09

2. Acute, chronic and conditioned effects of intranasal oxytocin in the mu-opioid receptor knockout mouse model of autism: Social context matters;Neuropsychopharmacology;2024-07-17

3. Hypothalamic vasopressin sex differentiation is observed by embryonic day 15 in mice and is disrupted by the xenoestrogen bisphenol A;Proceedings of the National Academy of Sciences;2024-05-16

4. Dietary nutrients that potentially mitigate autism spectrum disorder and dietary recommendations for children and pregnant women;Food Frontiers;2024-03-11

5. Acute, chronic and conditioned effects of intranasal oxytocin in the mu opioid receptor knockout mouse model of autism: social context matters;2024-03-10